United Therapeutics UTHR Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 352.1%-3.9pp | 354.5%-1.4pp | 355.8%+0.2pp | 356.2%+0.6pp | 356%-0.6pp | |
| Operating margin | 187%-2.5pp | 188.6%-4.3pp | 189.5%-6.4pp | 188.2%-11.2pp | 189.4%-13.2pp | |
| Net margin | 163.6%+0.4pp | 163.4%-1.4pp | 163%-2.6pp | 162.6%-3.4pp | 163.1%-3.3pp | |
| Returns | ||||||
| Return on equity | 79.3%+2.1pp | 79%+1.6pp | 78.5%+2.1pp | 77.3%+2.2pp | 77.2%+3.4pp | |
| Efficiency | ||||||
| Asset turnover | 1.7×+0.1× | 1.7×+0.1× | 1.7×+0.1× | 1.6×+0.2× | 1.6×+0.2× | |
| Liquidity | ||||||
| Current ratio | 25.1×+5.4× | 25.7×+7.8× | 24.4×+7.2× | 22.5×+5.4× | 19.6×-1.9× | |
| Per Share | ||||||
| Book value per share | $561.02+8.1% | $576.06+18.5% | $560.78+18.4% | $547.51+18.3% | $518.92+14.8% | |
| Valuation | ||||||
| Market capitalization | $79.01B+30.6% | $66.86B+16.4% | $61.63B+18.5% | $58.59B+25.5% | $60.48B+43.7% | |
| Price / earnings | 61.3×+8.4× | 52.6×+0.8× | 50.1×+1.0× | 49.5×+2.9× | 52.9×+8.5× | |
| Price / sales | 25.1×+3.5× | 21.5×+0.2× | 20.4×+0.2× | 20.1×+0.8× | 21.6×+3.1× | |
| Price / book | 12.1×+2.3× | 9.7×0.0× | 9.2×+0.2× | 8.9×+0.7× | 9.7×+2.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are United Therapeutics's profit margins?
- United Therapeutics (UTHR) runs a 86.6% gross margin and a 45.3% operating margin, with a 40.6% net margin.
- Where do United Therapeutics's ratios come from?
- Every ratio is computed from United Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
